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Abstract
Background: The IL-23/Th17 pathway is implicated in the pathogenesis of a number of chronic inflammatory and
autoimmune diseases. Whether it regulates the viral myocarditis (VMC) is unknown.
Results: To examine the pathogenesis role of IL-23/Th17 axis in VMC, we used male BALB/c mice to induced VMC
by Coxsackie virus B3 (CVB3) peritoneal injection. IL-23, IL-17, and signal transducer and activator of transcription 3
(STAT3) mRNA in the myocardium of VMC mice were assessed by semi-quantitative RT-PCR. IL-23 and IL-17 protein
from blood serum were evaluated by ELISA. Phosphorylated-STAT3 (p-STAT3) protein expression in the myocardium
was evaluated by immunohistochemical staining. Flow cytometric analysis was used to evaluate the frequencies of
Th17 subsets. Isolated CD4
+ T cells from VMC mice were cultured with recombinant IL-23(rIL-23) in vitro.I n
addition, a STAT3-specific inhibitor (S3I-201) was used to test whether regulation of STAT3 could be partly
responsible for Th17 diminution. Results showed that expression of IL-23, IL-17, STAT3 mRNA and protein increased
in VMC mice. When purified CD4
+ T cells derived from VMC mice were cultured in vitro with rIL-23, the frequency
of Th17 cells was dramatically increased, accompanied by significantly enhanced production of IL-17 in the
supernatants of cultured CD4
+ T cells. S3I-201 significantly restrained Th17 cell proliferation.
Conclusions: The IL-23/Th17 pathway axis is strongly expressed in murine VMC, identifying a novel pathway of
potential significance in viral myocarditis.
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Background
Viral myocarditis (VMC) has been recognized as a cause
of congestive heart failure for 50 years, but its diagnosis
and treatment are still challenging. Coxsackie virus B3
(CVB3), a member of the Picornaviridae family, is the
leading cause of VMC and often progresses to chronic
myocarditis, dilated cardiomyopathy (DCM), and conges-
tive heart failure, requiring heart transplantation [1].
Infection by CVB3 in a BALB/c murine model can induce
myocarditis with a pathological process resembling
human disease, and thus this model has been widely used
for studying both the acute infectious phase and chronic
immune phase of human VMC and cardiomyopathy [2].
Both the direct viral response and the excessive immune
response (mediated especially by activated CD4
+ Tl y m -
phocytes) are the dominant causes of myocardial cell
damage. In the acute stage of myocarditis, the production
of autoantibodies mainly depends on the help of Th1
cells, which classical theories suggest are the main causa-
tive agent of myocarditis [3,4]. However, this concept has
been challenged by the finding that mice lacking a typical
Th1 cytokine (IFN-g) are still susceptible to experimental
autoimmune myocarditis (EAM) [5,6].
Two decades ago, Mosmann and Coffman proposed a
model wherein T helper (Th) cells are divided into func-
tional subsets on the basis of cytokine secretion, termed
Th1 and Th2 [7]. IFN-g and IL-12 initiate the differentia-
tion of Th1 cells that are characterized by high produc-
tion of IFN-g and are indispensable for clearing
intracellular pathogens. IL-4 triggers the differentiation
of Th2 cells which are pivotal in organizing host defense
against extracellular pathogens and in helping B cells to
produce antibodies. Over the past several years, much
progress has been made in understanding a distinct third
Th17 lineage composed of IL-17-producing T-cells, Th17
cells are distinguished from the Th1 and Th2 cells not
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its development independently of key signaling elements
that are central to Th1 or Th2 differentiation. This new
CD4+ subset is important in providing protection against
infection and maintaining chronic inflammatory diseases
in autoimmune disease [8-11]. IL-23, a cytokine of the
IL-12 family, is secreted as a heterodimer composed of a
p40 subunit, identical to the p40 subunit of IL-12, and a
unique p19 subunit, similar to the p35 subunit of IL-12.
Recent results have shown that IL-23 is required for full
acquisition of the pathogenic function and maintenance
of effector Th17 cells [12-14]. Signal transducer and acti-
vator of transcription 3 (STAT3) signal transduction has
emerged as a key component of Th17-dependent autoim-
mune processes, and STAT3 might affect the expression
of IL-17 by increasing the expression of retinoid-related
orphan receptor gamma t (RORgt) and retinoid-related
orphan receptor alpha (RORa), which are upstream of
IL-17 [15,16]. The IL-23/Th17 pathways are involved in
the pathogenesis of rheumatoid arthritis, systemic lupus
erythematosus, psoriasis, and other autoimmune diseases.
These findings indicate the importance of the IL-23/
Th17 axis in inflammatory and autoimmune responses.
However, it is still largely unknown whether the IL-23/
Th17 axis is involved in the regulation of myocardial
inflammation. In this study, we examined whether the
IL-23/Th17 cell axis is involved in myocarditis using a
murine model of VMC induced by CVB3. We tested IL-
23, IL-17, and Th17-specific transcription factor STAT3
mRNA expression in the myocardial tissue of VMC mice,
IL-23 and IL-17 protein expression in serum, and phos-
phorylated-STAT3 (p-STAT3) expression in myocar-
dium. We also evaluated the frequencies of Th17 subsets
in spleen CD4
+ T cells. Finally, we assessed the possible
modulating effect of recombinant IL-23 (rIL-23) and a
STAT3-specific inhibitor (S3I-201) on Th17 cells in vitro.
Materials and methods
Animals
Specific pathogen-free inbred male BALB/c mice (6-
weeks old) were purchased from Shanghai Laboratory
Animal Center, Chinese Academy of Sciences, Shang-
hai, China (Certificate No.0062353 -SCXK (SH) 2007-
0005). All animals were housed in a pathogen-free
mouse room in an experimental animal center
(Guangxi Medical University).
Ethics Approval
The protocol was approved by the Committee on the
Ethics of Animal Experiments of the Guangxi Medical
University (ID: 20090622). All surgery was performed
under sodium pentobarbital anesthesia, and all efforts
were made to minimize suffering.
CVB3 Titration in Hep-2 Cells
Heart-passaged CVB3 (Nancy strain, from Institute of
immunology of Guangxi Medical University) was propa-
gated in Hep-2 cells, cultured in monolayer and stored
in a -80°C freezer. The supernatant from infected cell
cultures was collected, and viral titers were determined
in 96-well plates by the end-point dilution method.
Briefly, 10-fold serial dilutions (1:10 to 1:10
-10)o fp h o s -
phate-buffered solution (PBS, Solarbio Science & Tech-
nology, Beijing, China) were prepared, and the 50%
tissue culture infectious dose (TCID50) titer was deter-
mined by the cytopathic effects visible after 72 h. The
TCID50 assay result for Hep-2 cells was 1 × 10
-7.
Myocarditis
CVB3 was diluted in PBS, and BALB/c mice were
infected by an intraperitoneal (i.p.) injection of 0.1 ml of
PBS containing approximately 100 TCID50 of the virus (n
= 48) and randomly separated into 6 subgroups. Mice
inoculated i.p. with PBS were taken as control (n = 30)
and separated into 6 subgroups as well. The day when
mice were injected i.p was defined as week 0, and myo-
cardial tissues were harvested 0, 1, 2, 3, 4, and 6 weeks
after i.p. injection. Hearts were cut longitudinally, fixed
in 10% phosphate-buffered formalin, and embedded in
paraffin. The myocardial tissues were cut into 5-μm sec-
tions at various depths in the heart and stained with
hematoxylin & eosin to determine the level of inflamma-
tion, and graded in a blinded manner by a pathologist
based on the following semi-quantitative scale: 0, no
inflammatory infiltrates; 1, small foci of inflammatory
cells between myocytes or inflammatory cells surround-
ing individual myocytes; 2, larger foci of 100 inflamma-
tory cells or involving at least 30 myocytes; 3, 10% of a
myocardial cross-section involved; and 4, 30% of a myo-
cardial cross-section involved [17].
Immunohistochemistry
Immunohistochemical staining was performed by the
streptavidin-biotin complex method. Rabbit polyclonal
antibodies against mouse IL-17 (Santa Cruz Biotechnol-
ogy, USA) and p-STAT3 (Bioworld Technology, USA)
at a 1:100 dilution were used as primary antibodies. The
sections were washed and stained using the streptavidin-
biotin complex kit (Boster, Wuhan, China) according to
the manufacturer’s manual. The procedures were as fol-
lows: After the sections were rehydrated, endogenous
peroxidase activity was blocked with 3% hydrogen per-
oxide for 10 min at room temperature. After washing
with distilled water, the sections were first incubated in
5% bovine serum albumin for 20 minutes at room tem-
p e r a t u r ea n dt h e ni nt h ep r i m a r ya n t i b o d yf o r2 4ha t
4°C. Next, the sections were washed with PBS and then
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minutes. Finally, the sections were developed with 3, 3-
diaminobenzidine (Boster, Wuhan, China) and observed
under a light microscope (Eclipse E800, Nikon, Japan).
Non-immune goat serum was used instead of primary
antibody as a control. IL-17 and p-STAT3 deposition in
the cytoplasm and cytomembrane of myocardium were
categorized semi-quantitatively according to the extent
and intensity of staining using Image-Pro Plus Version
6.0 (Media Cybernetics, Bethesda, MD). Two pathology
experts randomly selected 5 fields from each slice for
blinded scoring and analysis by integrated optical den-
sity (IOD).
Lymphocyte preparation
Spleens from virus-infected mice and controls were har-
vested aseptically. The lymphocyte fractions of these
samples were obtained by Ficoll-Plaque (Solarbio
Science & Technology, China) gradient centrifugation.
Lymphocytes were maintained in a 24-well flat-bottom
tissue culture plate with RPMI 1640 supplemented with
10% fetal calf serum (Gibco, USA) at 37°C in a humidi-
fied atmosphere with 5% CO2.
Intracellular cytokine flow cytometry
Cytokine-producing cells were determined by intracellular
staining using phycoerythrin-conjugated anti-mouse IL-17
(IL-17-PE) and phycoerythrin cyanine-5-conjugated anti-
mouse CD4 (CD4-PE-Cy). Briefly, cells were stimulated
with phorbol myristate acetate (PMA, 25 ng/ml, Sigma-
Aldrich, USA), ionomycin (1 μg/ml, Sigma-Aldrich USA),
and GolgiPlug (1 μl/10
6 cells, BD Biosciences) for 4 h.
Cells were fixed in 4% paraformaldehyde, permeabilized
with 0.1% saponin, stained with fluorescent antibodies
against IL-17 and CD4, and analyzed on a FACSCalibur
flow cytometer (BD Biosciences). CellQuest software (BD
Biosciences) was used for data acquisition.
CD4
+ T cell cultured and rIL-23 stimulation
Spleen lymphocytes were isolated from mice 1 week after
CVB3 injection, and CD4
+ T cells were purified using a
CD4
+ T cell isolation kit (Miltenyi Biotec MACS, Bergisch
Gladbach, Germany). For culture, 10
6 CD4
+ T cells were
activated for 5 d with 10 ng/ml of phytohemagglutinin
(PHA) or 10 ng/ml of PHA + 10 ng/ml recombinant IL-23
(rIL-23, R&D). Cultured cells were restimulated with
PMA/ionomycin in the presence of GolgiPlug for intracel-
lular cytokine staining on day 6.
CD4
+T cell cultured with STAT3-specific inhibitor
Purified CD4
+ T cells (10
6/ml) were cultured in complete
culture medium with 10 ng/ml of PHA + 10 ng/ml recom-
binant IL-23 (rIL-23, R&D) with or without 100 μMo f
STAT3-specific inhibitor S3I-201 (NSC 74859, Santa Cruz
Biotechnology, CA). Concentrations of S3I-201 were
determined according to previously reports [18] and our
preliminary experiments by culturing cells in the presence
of increasing serial dosages of S3I-201. After 48 h of cul-
ture, cultured cells were restimulated with PMA/ionomy-
cin in the presence of GolgiPlug for intracellular cytokine
staining or for IL-17 mRNA transcript detection.
Semi-quantitative RT-PCR detection of IL-23, IL-17, and
STAT3 mRNA
Total mRNA was extracted from homogenized heart tis-
sues using TRIzol Reagent (Invitrogen, USA) and then
used to synthesize cDNA with an RT Kit (Ferma, USA).
Reverse-transcription PCR was performed with first-
strand cDNA synthesized with 1 μgo ft o t a lR N Aa n d
oligo d(T)16 primers according to the manufacturer’s
instructions. The primers for the RT-PCR assays for IL-
23p19, IL-17A, and Th17-specific transcription factor
STAT3 were designed by Primer Premier 5.0 (Table 1).
Mouse b-actin, a reference gene, was used to normalize
each sample and each gene. Prepared cDNA was used
for PCR amplification with the above primers under the
following conditions: pre-heating at 94°C for 3 min,
denaturing at 94°C for 30 sec, annealing at 64.3°C (IL-
23), 64.9°C (IL-17) or 56.8°C (STAT3) for 30 sec, and
extension at 72°C for 60 sec. The reaction repeated for
35 cycles followed by incubation at 72°C for 10 min.
PCR products were analyzed by electrophoresis on a 2%
agarose gel containing 0.5 mg/ml ethidium bromide.
The resulting bands were observed and photographed
under ultraviolet light and measured using the Digital
Gel Imaging Analyst (Nikon 990-Doc 1000, USA). Den-
sity was determined for each sample PCR product,
including the positive control. Background density was
subtracted from each band, and the relative values of
IL-23, IL-17, and STAT3 mRNA were calculated using
b-actin mRNA as a standard. PCR products was
sequenced by Songon Biotech Co., Ltd (Shanghai,
China), and blasted in the NCBI Blast bank.
Cytokine assay
Blood was collected via retro-orbital bleeding, and
serum was separated. The amounts of IL-23 and IL-17
Table 1 Sequences of primers for RT-PCR
Molecule Sequence (5’ -3’) length
IL-23 [GenBank:
83430]
sense: 5’CTTCTCCGTTCCAAGATCCTTC 3’
antisense:5’ACGCACTAGGTTTGCCGAGTAGA3’
200
bp
IL-17
[GenBank:16171]
sense:5’GTCAATGCGGAGGGAAAG3’
antisense: 5’CACGAAGCAGTTTGGGAC 3’
349
bp
STAT3 [GenBank:
20848]
sense: 5’CCCATATCGTCTGAAACTC3’
antisense: 5’TTGCTCCCTTCTGCTCT3’
188
bp
b-actin
[GenBank:11461]
sense:5’CCAGCCTTCCTTCTTGGGTAT3’
antisense: 5’TTGGCATAGAGGTCTTTACGG 3’
102
bp
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using the Quantified Mouse IL-23/IL-17 Immunoassay
(R&D Systems, Minneapolis, MN). The limits of detec-
tion were 2.28 and 5 pg/ml.
Statistical analysis
All data were expressed as mean ± SD. One-way
ANOVA and the q test were used for comparison
among groups. All data were analyzed with SPSS 16.0
for Windows. A significant difference was defined as
P < 0.05.
Results
Development of VMC
CVB3-inoculated mice developed myocarditis one week
after CVB3 infection, exhibiting with the symptoms of ill-
ness, including lethargy, progressive weight loss, and even
death. The mice in control group remained healthy
throughout the study. Histopathological observations of
heart tissues were characterized by focal cellular infiltra-
tion with little necrosis or fibrosis, whereas no changes
were seen in the controls [Figure 1A]. The pathological
scores of the heart sections in the VMC group were signif-
icantly elevated compared with those in the control group
[Figure 1B] and were accompanied by progressive cardiac
i n f l a m m a t o r yl e s i o n st h a tp e a k e da tt h es e c o n dw e e k .
There were 8, 8, 5, 6, 6 and 5 mice remaining alive in each
VMC subgroup. No mice died in control group.
IL-23, IL-17 mRNA and protein expression were
significantly elevated in the myocardium of VMC mice
Results showed that IL-23 and IL-17 transcripts were
abundant in all samples from the first to the sixth week in
VMC mice [Figure 2A]. The highest level of these two
genes occurred on fourth week, while the expression of
these two genes in controls remained constant throughout
the procedure [Figure 2B, C]. IL-17 deposition in the cyto-
plasm and cytomembrane were positive in VMC mice 1-6
weeks after infection, which were statistical higher than
those in control mice, P <0 . 0 5[ F i g u r e2 D ,E ] .T h ei n t e -
grated optical density (IOD) of IL-17 protein in the myo-
cardium of VMC and control mice at different time points
were 35.98 ± 4.78 vs. 36.04 ± 5.46, 1516.41 ± 83.32 vs.
35.56 ± 4.51, 1700.95 ± 90.56 vs. 37.91 ± 6.70, 2013.95 ±
104.89 vs. 34.29 ± 8.43, 2570.12 ± 118.92 vs. 38.12 ± 9.52,
and 1878.95 ± 90.89 vs. 35.67 ± 7.69, respectively. IL-23
protein levels increased in the serum of VMC mice in the
first week [Figure 2F], peaked on the fourth week, and
maintained high level till sixth week. The serum IL-23
protein levels at different times during VMC were 15.39 ±
6.14, 26.48 ± 5.98, 29.93 ± 12.05, 29.40 ± 11.73, 37.44 ±
8.51, and 27.56 ± 6.16 pg/ml. IL-17 protein levels
increased in the serum of VMC mice from the first to the
sixth week [Figure 2G]. After reaching the highest level on
the fourth week, IL-17 sustained a high level till sixth
week. The serum IL-17 proteins levels at different times
during VMC were 11.88 ± 1.83, 19.64 ± 6.88, 22.70 ± 9.18,
28.77 ± 2.96, 31.27 ± 9.80, and 22.67 ± 4.47 pg/ml.
Th17 frequencies were increased in the spleen one week
after viral infection
Compared to the controls, the frequencies of Th17 cells
were markedly increased in VMC mice from the first week
after viral infection [Figure 3A, B]. All of the results at dif-
ferent times were higher than those of controls except 0
week, P < 0.05. Th17 frequencies in each subgroup of
VMC and control mice were 0.77 ± 0.32% vs. 0.89 ±
0.47%, 2.23 ± 0.89% vs. 0.95 ± 0.15%, 2.71 ± 0.82% vs.
0.80 ± 0.07%, 2.72 ± 0.64% vs. 0.96 ± 0.47%, 5.00 ± 0.81%
vs. 0.98 ± 0.47%, and 2.35 ± 0.35% vs. 1.08 ± 0.66%
respectively.
STAT3 mRNA and p-STAT3 were high expressed in
myocardium of VMC mice
Results showed that the expression of the Th17-specific
transcription factor STAT3 mRNA was clearly elevated
from the first week to the sixth week [Figure 4A, B]. The
expression of this gene in controls remained constant
throughout the procedure. Immunohistochemistry showed
that p-STAT3 protein expressed in myocardium of VMC
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Figure 1 Histopathologic changes of heart tissue in VMC mice.
A. Representative image of inflammation in VMC heart tissue (H&E,
original magnification × 400). B The pathological scores at different
times, *P < 0.05, versus control group,
ΔP < 0.05, versus week 0, 1, 3,
4, and 6 VMC mice,
※P < 0.05, versus week 4 and 6 VMC mice. The
number of mice in each time point of VMC group was 8, 8, 5, 6, 6
and 5 respectively. The number of mice in each time points of
control was 5.
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IOD of p-STAT3 protein in the myocardium of VMC and
control mice at different time points were 33.67 ± 14.56
vs. 30.04 ± 12.90, 1234.41 ± 110.45 vs. 31.56 ± 13.45,
1600.95 ± 124.37 vs. 30.91 ± 19.30, 2070.12 ± 139.20 vs.
32.29 ± 17.82, 2524.25 ± 123.64 vs. 31.12 ± 16.89, and
1784.95 ± 130.19 vs. 33.67 ± 15.67, respectively.
Th17 frequencies were increased by rIL-23 stimulation
Those above results showed that IL-23/Th17 pathway is
present in murine model of VMC. To confirm our in
vivo data, we next cultured CD4
+ cells in vitro with rIL-
23 to analyze cytokine production and Th17 cells. As
our previous research had shown that Th17 cell
increased one week after virus infection [17], we isolated
CD4
+ T cells by MACS from BALB/c mice one week
after CVB3 infection. The purity of CD4
+ Tc e l li s o l a -
tion was always >93%, as determined by flow cytometry.
Cells were cultured in the presence of PHA (10 ng/ml)
and rIL-23(10 ng/ml) or PHA (10 ng/ml) alone. After
five days of culture, CD4-specific IL-17-producing Th17
cells were identified by FCS after PMA/ionomycin resti-
mulation. Results showed that administration of rIL-23
promoted the expansion of Th17 cells (1.82 ± 0.17% vs.
4.70 ± 1.29%, P < 0.05) [Figure 5A, B], Corresponding,
I L - 1 7a n dS T A T 3m R N Ae x p r e s s i o ni nt h ec u l t u r e d
Figure 2 IL-23, IL-17 mRNA and protein expression in the myocardium of mice. A. Strong expression of IL-23, IL-17 occurred from the first
week to the sixth week after CVB3 infection inVMC mice. M: Maker; 1: week 0; 2: week 1; 3: week 2; 4: week 3; 5: week 4; 6: week 6. B.
Densitometric quantitation of IL-23. IL-23 mRNA expression was elevated in VMC mice from the first week to the sixth week.
ΔP < 0.01, versus
control group,
ΔP < 0.05, versus week 0, 1, and 2 VMC mice. C. Densitometric quantitation of IL-17. IL-17 mRNA expression was elevated in VMC
mice from the first week, and the arbitrary units were higher than those of controls.
ΔP < 0.01 versus controls,
ΔP < 0.05, versus week 0 VMC
mice. D. Representative of IL-17 immunohistochemistry images in heart tissue of VMC mice (Dark brown granules, original magnification × 400).
E. Morphometric quantitation of IL-17 protein expression.
ΔP < 0.01, versus control group,
ΔP < 0.05, versus week 0, 1, 2 and 6 VMC mice. F. IL-23
protein levels were steadily increased in the VMC mice,
ΔP < 0.05, versus control group,
ΔP < 0.05, versus week 0, and 6 VMC mice. G, IL-17
protein levels were steadily increased in the VMC mice from 1 week after i.p, and reached statistical difference comparing with those of controls,
ΔP < 0.05. The highest level of IL-17 in VMC occurred on 4th week,
ΔP < 0.05, versus week 0, 1 VMC mice.
※P < 0.05, versus week 0, 1 VMC mice.
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increased after rIL-23 stimulation [Figure 5C, D, E]. The
IL-17 protein levels in the culture supernatants were
15.45 ± 5.67 vs.63.31 ± 12.94 pg/ml, respectively,
P < 0.01.
Th17 frequencies were decreased by treatment with S3I-
201
We used S3I-201, a STAT3-specific inhibitor, to test
whether regulation of p-STAT3 could be partly responsi-
ble for IL-17 diminution. This agent selectively abrogates
STAT3 DNA-binding activity in vitro by blocking the
formation of STAT3:STAT3 dimers and is more than
threefold more selective for STAT3 over STAT1. Results
showed that administration of S3I-201 decreased the
expansion of Th17 cells (5.02 ± 0.72% vs. 3.85 ± 0.69%, P
< 0.05) [Figure 6A, B]. Correspondingly, IL-17 and
STAT3 mRNA expression in the cultured cells and IL-17
protein levels in the culture supernatants decreased after
S3I-201 inhibition [Figure 6C, D, E]. The IL-17 protein
levels in the culture supernatants were 55.34 ± 10.78 vs.
30.28 ± 7.56 pg/ml, respectively, P < 0.01.
Discussion
IL-12 mediated Th1 responses had been believed to
increase CVB3-induced myocarditis in susceptible
BALB/c mice, but results showed that IL-12 deiciency
did not prevent the development of acute myocarditis
[12], and mice lacking IFN-g were highly susceptible to
Figure 3 Th17 frequencies in VMC mice.A .R e p r e s e n t a t i v e
pictures of CD4
+IL-17
+ Th17 cells in VMC mice. Numbers in the
upper right quadrants indicate the mean percentages of CD4
+ Th17
cells in VMC mice. B. The results of the Th17 cells statistical analysis.
ΔP < 0.01, versus control group.
ΔP < 0.05, versus week 0, 1, 2, 3,
and 6 VMC mice.
Figure 4 STAT3 mRNA and p-STAT3 protein expression in the myocardium of VMC mice. A. Strong expression of STAT3 occurred from 1st
week to 6th week after CVB3 infection. M: Maker; 1: week 0; 2: week 1; 3: week 2; 4: week 3; 5: week 4; 6: week 6. B. Densitometric quantitation
of STAT3. STAT3 mRNA expression was elevated in VMC mice from 1st week to 6th week,
ΔP < 0.01, versus control group.
ΔP < 0.05, versus week
0, 1 and 2. C. Representative of p-STAT3 immunohistochemistry images in heart tissue of VMC mice (Dark brown stain in cytoplasm, original
magnification × 400). D. Morphometric quantitation of p-STAT3 protein expression in heart.
ΔP < 0.05, versus control group,
ΔP < 0.05, versus
week 0, 1, 2 VMC mice.
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or play decisive roles in myocardial autoimmune injury.
At the same time, emerging data suggest that Th17 cells
may play very important roles in VMC [19-21]. In
addition, the IL-23/IL-17 axis, but not the IL-12/IFN-g
axis, is critical for the pathogenesis and development of
certain autoimmune inflammatory diseases, such as
inflammatory bowel disease and EAE [22-25]. However,
Figure 5 Th17/IL-17 production stimulated by rIL-23. A. Representative pictures of CD4
+IL-17
+ Th17 cells stimulated by rIL-23. The numbers
in the upper right quadrants represents the mean percentage of Th17 in response to 5 d of culture with or without IL-23. B. The results of Th17
cells statistical analysis. *P < 0.05. C. Strong expression of IL-17 and STAT3 after rIL-23 stimulation. D. Densitometric quantitation of IL-17 and
STAT3 mRNA in the cultured cells after rIL-23 stimulation. *P < 0.05. E. IL-17 protein levels in the culture supernatant were significantly increased
after rIL-23 stimulation *P < 0.01.
Figure 6 Intracellular IL-17 production inhibited by S3I-201. A. Representative pictures of CD4
+IL-17
+ Th17 cells inhibited by S3I-201. The
numbers in upper right quadrants represent the mean percentage of Th17 cells in response to S3I-201. B. The results of Th17 cells statistical
analysis, *P < 0.05. C. Decreased expression of IL-17 and STAT3 after S3I-201 inhibition. D. Densitometric quantitation of IL-17 and STAT3 mRNA
in the cultured cells after S3I-201 inhibition. *P < 0.05. E. IL-17 protein levels in the culture supernatant were significantly decreased after S3I-201
inhibition, *P < 0.01.
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of VMC is unknown.
This study observed the role of the IL-23/Th17 axis in
VMC mice. Using semi-quantitative RT-PCR, we found
that IL-23 and IL-17 mRNA expression was elevated in
VMC mice immediately after CVB3 incubation, and the
Th17-specific transcription factor STAT3 was robustly
elevated compared to controls. IL-23, IL-17, and STAT3
protein levels were also higher in VMC mice than in
controls. IL17-producing CD4
+ T cells were more abun-
dant in the VMC mice. We next investigated whether
the IL-23/Th17 pathway is important during a CVB3
challenge. We found that IL17-producing CD4
+ T cells
were significantly higher in the presence of rIL-23 and
accompanied by increased IL-17 transcription and pro-
tein levels, STAT3 specific inhibitor can decrease the
frequency of Th17 cells. These results are consistent
with papers suggesting that IL-23 is required for the
development and expansion of Th17 cells [13,26]. The
molecular mechanisms by which an adaptive immune
response is skewed toward a Th17 response appear to
rely in part on the ability of specific cytokines, specifi-
cally IL-23, that favor the development of Th17 cells.
Activated macrophages and dendritic cells (DCs) secrete
IL-23 in response to environmental danger signals. The
receptor for IL-23 was described as being expressed in
activated/memory T cell populations (but not in naive T
cells) and specifically on Th17 cells. Furthermore, stu-
dies have proposed that IL-23R could be induced in a
STAT3-dependent manner by TGF-b, IL-6, and IL-21
[27,28], and IL-23R also appears to be dependent on
RORgt [29]. Th17 cells require activation of STAT3 and
subsequent RORgt induction. STAT3 activation is
induced by IL-6, IL-21, and IL-23, and activated STAT3
directly binds to the STAT-binding sites on the IL-17
gene promoter, increases IL-17 gene transcription, and
then affects the expression of IL-17 by increasing the
expression of RORgta n dR O R a [15,16]. Therefore,
STAT3 and RORgt seem to cooperate, and competent
production of IL-17 depends on the presence of both
transcription factors. The present study suggests that,
upon stimulation with CVB3, pathogen-associated mole-
cular patterns activate specific Toll-like receptors
(TLRs) or dectin receptors, and DCs secrete IL-23 along
with other cytokines such as IL-6, IL-21 and TGF-b.I n
addition, the combined signals of RORgta n dS T A T 3
might promote IL-23R expression. When the IL-23
cytokine signal becomes dominant, it skews toward the
type of immunity that develops Th17 cells and confers
responsiveness to IL-23/Th17. As a result, IL-23 and IL-
17 mRNA expression and protein secretion would be
abnormally elevated.
Some limitations need to be acknowledged. First, like
most cytokine receptors, IL-23R is expressed at low
levels, and it is difficult to purify Th17 cells on the basis
of IL-23R expression. An alternative selection sign is the
chemokine receptor CCR6, which is reported to be a
predominant marker of Th17 cells. CCR6 expression on
CD4
+ T cells is able to distinguish Th17 cells from most
other Th cells, with the possible exception of a subset of
Treg [30]. However, CCR6-expressing Th17 and Treg
cells may coexist in inflamed tissue in the context of an
inflammatory condition [31,32]. As a result, we could
n o ti s o l a t eas p e c i f i cs u b p o p u l a t i o no fT h 1 7c e l l si n
VMC mice to culture in vitro. Second, besides being
produced by Th17 cells, IL-17 is also produced by a
variety of cell types, including gδT cells, NKT cells, NK
cells, neutrophils, and eosinophils, and whether these
IL-17-producing cells contribute to the pathogeneses of
myocardium injury during VMC needs more research.
In summary, we have demonstrated that the IL-23/Th17
pathway is frequently induced in a murine model of VMC,
and this pathway may therefore play a pathogenic role in
VMC. However, the precise function of IL-23 in Th17
cells remains elusive, in part because the timing and con-
sistency of IL-23R expression in T cells have been difficult
to investigate. Furthermore, autoimmune diseases have so
far been associated with Th1 and Th17 cells. Although the
latest advances, together with ours, suggest that Th17 is a
driving factor of disease pathogenesis in VMC, data sug-
gested that Th1 cells can induce myocarditis with severity
similar to Th17 cells [33], IL-17A knockout mice are not
fully protected against EAM and still develop mild myo-
carditis [34]. In addition to these, results show that a
severe autoimmune disease can be elicited in the absence
of IFN-g and IL-17, the prototypic Th1 and Th17 cyto-
kines. Besides, because both IFN-g
+ and IL-17
+ CD4
+ T
cells can be detected in diseased mice[35,36], Is myocardi-
tis a simple Th1 or Th17 driven disease, or there is consid-
erable overlap between the developmental pathways that
produce IFN-g
+ and IL-17
+ effector cells? Probably, a
model of disease pathogenesis in either Th17 cells or Th1
cells favor disease is too simplistic, comparative studies are
required to further reveal the roles of these cytokines in
the pathogenesis of immune-related diseases.
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